SG11201407337QA - Cyclodextrin complexation methods for formulating peptide proteasome inhibitors - Google Patents
Cyclodextrin complexation methods for formulating peptide proteasome inhibitorsInfo
- Publication number
- SG11201407337QA SG11201407337QA SG11201407337QA SG11201407337QA SG11201407337QA SG 11201407337Q A SG11201407337Q A SG 11201407337QA SG 11201407337Q A SG11201407337Q A SG 11201407337QA SG 11201407337Q A SG11201407337Q A SG 11201407337QA SG 11201407337Q A SG11201407337Q A SG 11201407337QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lllll
- proteasome inhibitors
- methods
- llll
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 5
- 229940079156 Proteasome inhibitor Drugs 0.000 title abstract 4
- 238000010668 complexation reaction Methods 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000003207 proteasome inhibitor Substances 0.000 title abstract 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229940097362 cyclodextrins Drugs 0.000 abstract 3
- 229960002438 carfilzomib Drugs 0.000 abstract 1
- 108010021331 carfilzomib Proteins 0.000 abstract 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644122P | 2012-05-08 | 2012-05-08 | |
| US201361777475P | 2013-03-12 | 2013-03-12 | |
| PCT/US2013/040127 WO2013169897A1 (en) | 2012-05-08 | 2013-05-08 | Cylodextrin complexation methods for formulating peptide proteasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407337QA true SG11201407337QA (en) | 2014-12-30 |
Family
ID=48326170
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407337QA SG11201407337QA (en) | 2012-05-08 | 2013-05-08 | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors |
| SG10201609318UA SG10201609318UA (en) | 2012-05-08 | 2013-05-08 | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201609318UA SG10201609318UA (en) | 2012-05-08 | 2013-05-08 | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10159746B2 (de) |
| EP (2) | EP4410374A2 (de) |
| JP (1) | JP6410264B2 (de) |
| KR (5) | KR20240119191A (de) |
| CN (2) | CN104411334A (de) |
| AU (2) | AU2013259573B2 (de) |
| CA (1) | CA2873044C (de) |
| CL (1) | CL2014003055A1 (de) |
| DK (1) | DK2662094T3 (de) |
| EA (1) | EA033614B1 (de) |
| ES (1) | ES2981576T3 (de) |
| FI (1) | FI2662094T3 (de) |
| HK (2) | HK1207827A1 (de) |
| HR (1) | HRP20240724T1 (de) |
| HU (1) | HUE066956T2 (de) |
| IL (1) | IL235553B (de) |
| LT (1) | LT2662094T (de) |
| MX (2) | MX364393B (de) |
| PL (1) | PL2662094T3 (de) |
| PT (1) | PT2662094T (de) |
| RS (1) | RS65647B1 (de) |
| SG (2) | SG11201407337QA (de) |
| SI (1) | SI2662094T1 (de) |
| WO (1) | WO2013169897A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015009888A2 (en) | 2013-07-19 | 2015-01-22 | Onyx Therapeutics, Inc. | Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers |
| CN104945470B (zh) * | 2014-03-30 | 2020-08-11 | 浙江大学 | 杂环构建的三肽环氧酮类化合物及制备和应用 |
| KR102655020B1 (ko) | 2016-06-29 | 2024-04-04 | 케자르 라이프 사이언스 | 펩티드 에폭시케톤 면역프로테아좀 억제제의 결정질 염 |
| EA201990157A1 (ru) | 2016-06-29 | 2019-05-31 | Кезар Лайф Сайнсиз | Способ получения пептидного эпоксикетонового ингибитора иммунопротеасомы и его предшественников |
| WO2018038687A1 (en) | 2016-08-22 | 2018-03-01 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex |
| TWI773706B (zh) * | 2016-11-29 | 2022-08-11 | 瑞士商歐庫利斯公司 | 用於眼用活性藥物成分輸送的固體環糊精複合物之製備 |
| AU2018263924B2 (en) * | 2017-05-03 | 2024-07-04 | Cydex Pharmaceuticals, Inc. | Composition containing cyclodextrin and busulfan |
| EP3993807A1 (de) | 2019-07-01 | 2022-05-11 | Oculis SA | Verfahren zur stabilisierung des ph einer wässrigen zusammensetzung mit einem arzneimittel |
| CN110882221B (zh) * | 2019-11-29 | 2021-06-29 | 健进制药有限公司 | 一种注射用卡非佐米冻干制剂的生产工艺 |
| WO2022159319A2 (en) * | 2021-01-19 | 2022-07-28 | Mountain Valley Md Inc | A porous aluminum nanoparticulate structure |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| DE19505263A1 (de) * | 1995-02-16 | 1996-08-22 | Consortium Elektrochem Ind | Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten |
| WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| GB9713149D0 (en) | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
| PT889056E (pt) | 1997-07-01 | 2006-07-31 | Pfizer Prod Inc | Processo para produzir um,a ciclodextrina. |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
| DE50110956D1 (de) | 2000-10-12 | 2006-10-19 | Viromics Gmbh | Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen |
| NZ548225A (en) * | 2003-12-31 | 2012-12-21 | Cydex Pharmaceuticals Inc | Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| CN102174076A (zh) | 2004-04-15 | 2011-09-07 | 普罗特奥里克斯公司 | 用于抑制蛋白酶体酶的化合物 |
| DK1819353T3 (da) * | 2004-12-07 | 2011-05-16 | Proteolix Inc | Sammensætning til proteasomhæmning |
| BRPI0618653A2 (pt) * | 2005-11-15 | 2011-09-06 | Baxter Int | composições compreendendo inibidores da lipoxigenase e ciclodextrina |
| KR20150131405A (ko) * | 2007-10-04 | 2015-11-24 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| EP2349313A4 (de) | 2008-10-21 | 2012-08-29 | Onyx Therapeutics Inc | Kombinationstherapie mit peptidepoxyketonen |
| KR20200106100A (ko) | 2012-02-28 | 2020-09-10 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
-
2013
- 2013-05-08 CN CN201380036466.0A patent/CN104411334A/zh active Pending
- 2013-05-08 AU AU2013259573A patent/AU2013259573B2/en active Active
- 2013-05-08 US US14/399,582 patent/US10159746B2/en active Active
- 2013-05-08 KR KR1020247025639A patent/KR20240119191A/ko active Search and Examination
- 2013-05-08 CN CN201710866757.2A patent/CN107693772A/zh active Pending
- 2013-05-08 CA CA2873044A patent/CA2873044C/en active Active
- 2013-05-08 FI FIEP13167148.9T patent/FI2662094T3/fi active
- 2013-05-08 SG SG11201407337QA patent/SG11201407337QA/en unknown
- 2013-05-08 HU HUE13167148A patent/HUE066956T2/hu unknown
- 2013-05-08 KR KR1020227020311A patent/KR20220088949A/ko active Application Filing
- 2013-05-08 SG SG10201609318UA patent/SG10201609318UA/en unknown
- 2013-05-08 HR HRP20240724TT patent/HRP20240724T1/hr unknown
- 2013-05-08 PL PL13167148.9T patent/PL2662094T3/pl unknown
- 2013-05-08 EP EP24170493.1A patent/EP4410374A2/de active Pending
- 2013-05-08 PT PT131671489T patent/PT2662094T/pt unknown
- 2013-05-08 WO PCT/US2013/040127 patent/WO2013169897A1/en active Application Filing
- 2013-05-08 RS RS20240704A patent/RS65647B1/sr unknown
- 2013-05-08 DK DK13167148.9T patent/DK2662094T3/da active
- 2013-05-08 EA EA201491994A patent/EA033614B1/ru not_active IP Right Cessation
- 2013-05-08 SI SI201332084T patent/SI2662094T1/sl unknown
- 2013-05-08 EP EP13167148.9A patent/EP2662094B1/de active Active
- 2013-05-08 KR KR1020207032107A patent/KR20200130748A/ko not_active IP Right Cessation
- 2013-05-08 KR KR1020147034238A patent/KR102054329B1/ko active IP Right Grant
- 2013-05-08 KR KR1020197035904A patent/KR20190137963A/ko not_active Application Discontinuation
- 2013-05-08 ES ES13167148T patent/ES2981576T3/es active Active
- 2013-05-08 JP JP2015511660A patent/JP6410264B2/ja active Active
- 2013-05-08 LT LTEP13167148.9T patent/LT2662094T/lt unknown
- 2013-05-08 MX MX2014013552A patent/MX364393B/es active IP Right Grant
-
2014
- 2014-11-06 IL IL235553A patent/IL235553B/en active IP Right Grant
- 2014-11-07 MX MX2019004845A patent/MX2019004845A/es unknown
- 2014-11-10 CL CL2014003055A patent/CL2014003055A1/es unknown
-
2015
- 2015-09-01 HK HK15108517.0A patent/HK1207827A1/xx unknown
-
2018
- 2018-01-19 AU AU2018200444A patent/AU2018200444B2/en active Active
- 2018-08-14 HK HK18110388.9A patent/HK1250927A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407337QA (en) | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| CA2859619C (en) | Bromodomain inhibitors | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201408539UA (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201402986RA (en) | Kinase inhibitors | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia |